Inhibitor Therapeutics, Inc. (INTI)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | - | - |
| Research and development | 325,623 | 236,058 | 319,621 | 239,776 |
| General and administrative | 370,150 | 438,493 | 493,575 | 345,371 |
| Total expenses | 695,773 | 674,551 | 813,196 | 585,147 |
| Loss from operations | -695,773 | -674,551 | -813,196 | -585,147 |
| Interest income | 35,831 | 41,705 | 82,239 | 83,457 |
| Net loss | -659,942 | -632,846 | -730,957 | -501,690 |
| Basic net loss per share | - | - | - | - |
| Diluted net loss per share | - | - | - | - |
| Weighted average common stock shares outstanding - basic | 172,573,545 | 172,323,545 | 172,323,545 | 172,323,545 |
| Weighted average common stock shares outstanding - diluted | 172,573,545 | 172,323,545 | 172,323,545 | 172,323,545 |